
On Saturday, AstraZeneca Plc (NASDAQ:AZN) released full results from the BaxHTN Phase 3 trial evaluating baxdrostat. The company released the topline data in July.
The study showed baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks.